Resurgence of Mycoplasma Pneumonia by Macrolide-Resistant Epidemic Clones in China

Heng Li,Shengkai Li,Haitang Yang,Zhengrong Chen,Zhemin Zhou
DOI: https://doi.org/10.1016/s2666-5247(23)00405-6
2024-01-01
Abstract:In The Lancet Microbe, Patrick M Meyer Sauteur and colleagues1 reported about a delayed re-emergence of Mycoplasma pneumoniae after the COVID-19 pandemic restrictions. According to initial study findings, China is currently facing a concurrent outbreak of paediatric respiratory diseases, particularly the macrolide-resistant M pneumoniae (MRMP) outbreak.2 On the basis of more than 30 000 PCR tests and bronchoscopy findings (appendix p 3) in a paediatric hospital in east China from 2017 to 2023, we found a pronounced re-emergence of M pneumoniae, with up to 50% positive cases noted since July, 2023 (appendix p 2), compared with a lower incidence of positive cases ranging from 10% to 20% during the COVID-19 period (2020–22).
What problem does this paper attempt to address?